Product Pipeline

A number of targeted anticancer compounds are now in clinical testing through our own product programs and those of our partners. Information on the relevant subtypes of each cancer can be found in the discussion of each compound.


ProgramIndicationPre-Clinical  Phase I  Phase IIPhase IIIApproved

IMGN853
FRα+
solid tumors


     

IMGN289
EGFR+
solid tumors


     

IMGN529

NHL


     

IMGN779

AML



     
Kadcyla®

HER2+ mBC
2nd line




 
HER2+ mBC
1st line






HER2+ BC
others




 


Kadcyla®


HER2+ gastric




 


SAR3419

DLBCL



 

 

SAR650984*

Multiple myeloma



 

 

SAR566658

CA6+
solid tumors


     

SAR408701

CECAM5+
solid tumors


     
Sanofi 5 Undisclosed        
BT-062
 
Multiple myeloma      
Breast, bladder cancer      

BAY 94-9343
Mesothelin+
solid tumors
 
     

AMG 595

Gliomas
 
     

AMG 172

ccRCC
 
     

Amgen 3

Undisclosed
         

Amgen 4/OBT

Undisclosed
         

Lilly 1
 
Undisclosed
         

LOP628
 
cKIT+ cancer
         

Novartis 2
 
Undisclosed
         

Novartis 3
 
Undisclosed
         
Additional earlier stage compounds in development by ImmunoGen and our partners.
ImmunoGen Roche
Sanofi Biotest
Bayer Amgen
 Lilly Novartis

Kadcyla® is a registered trademark of Genentech.

* Naked antibody

FRα: folate receptor alpha, also known as folate receptor 1 (FOL1)
EGFR: epidermal growth factor receptor
NHL: Non-Hodgkin lymphoma 
AML: Acute myeloid leukemia
HER2: human epidermal growth factor 2
mBC: metastatic breast cancer
BC: breast cancer
DLBCL: Diffuse large B-cell lymphoma
ccRCC: clear cell renal cell carcinoma


Last updated August 28, 2014